🔗 Share this article

Given that the United States proceeds with sweeping adjustments to its vaccination recommendations, an unexpected name has emerged in a surprising turn: Høeg, a US-based sports medicine doctor and public health researcher who rose to prominence by casting doubt on coronavirus vaccines throughout the global health crisis and has concentrated on potential deaths following Covid vaccination in her short position at the Food and Drug Administration.

Planned Overhauls to Childhood Vaccine Schedule

Health officials planned to announce major revisions to the childhood immunization program in December, bringing the US with the Danish vaccine program, according to reports – a substantial departure that would put the US at odds with a large portion of the international standard with no evidence for improved outcomes. The announcement has been postponed until the coming year.

Instead of the top vaccines chief, Tracy Beth Høeg is listed to address the audience at the event. She was just designated interim head of the FDA’s drug evaluation center, the fifth person to run the office this year.

A New Direction at the Agency

The acting appointment may indicate a strengthened alliance between the drug and vaccine centers as Høeg and Prasad solidify control at the agency – and it suggests a increased emphasis upon rolling back already-approved vaccines at the FDA.

The new acting director has frequently advocated for halting certain pediatric immunization guidelines in the US in order to be more like Denmark, a country with universal health coverage and a population roughly the population of the state of Wisconsin.

So far public appearances, she has persisted in emphasizing on immunizations – usually the responsibility of Prasad, director of the FDA’s vaccine center – instead of medication approval.

Questions Over Background

Dr. Høeg has little discernible background in pharmaceutical research, approval processes or leadership, which has been customary for former leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the commissioner and the vaccine center since spring.

“It seems she lacks to have any of the qualifications” for leading the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She has not conducted a clinical trial. She is not versed in leading a major agency. She has no expertise in pharmaceutical oversight.”

Past heads of CBER would “be deeply familiar with legal statutes and the research of pharmaceutical innovation”, said Dr. Janet Woodcock. “Clearly, she doesn’t have the sort of resume that previous people who led the center have had.”

The drug center has an immense range of responsibilities at the agency, the former commissioner pointed out.

“Many people just pays attention on the new drug program, but the generic program authorizes numerous generic medications. There is also a biosimilars division, non-prescription drug unit and other areas, and all of those need to be supervised,” Woodcock said. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a significant leadership aspect to the job, which manages more than 5,000 personnel. “It is a massive management job, if you perform it correctly,” she concluded.

Response and Controversial Programs

Regarding questions about Dr. Høeg's qualifications and whether this selection indicates more teamwork among FDA leaders on vaccines, a representative responded that the “inquiries stem from inaccurate premises”.

“Her experience aligns with the functions of her job,” the representative stated, citing the time Høeg spent counseling the agency head on “drug safety and approval science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Høeg inherits the agency head's controversial fast-track approval initiative, a controversial expedited therapy clearance system that reportedly concerned her former heads. “By what process are these medications being chosen for this fast-track system? Who takes the decisions?” Dr. Howard said. “There’s a lot of secrecy happening at the regulatory body right now.”

Overall, he stated, “the agency seems to be moving towards laxer regulations of pharmaceuticals, with the exception of shots.”

Public Past Work on Vaccines

Regarding immunizations, Høeg has a clearer, if concerning, past, critics have noted. She published a research paper using unverified public submissions to assess the incidence of myocarditis after COVID-19 vaccination. She consulted for the Florida surgeon general Joseph Ladapo, who allegedly have modified findings to imply COVID-19 vaccinations are more dangerous than they are.

Among her “wish list” for the new federal leadership encompassed revising regulations for novel immunizations and halting “non-essential” vaccines, she remarked post-election on a audio program. At the agency, Høeg has allegedly proposed preventing adolescent males from obtaining COVID-19 vaccinations.

“She is an thorough ideologue who begins with her beliefs and reverse-engineers to accommodate the science in a highly deceptive, untruthful manner,” Dr. Howard stated.

Taking Control and a “Campaign of Retribution”

Høeg joined fellow dissenters, {like|